KR20120036842A - 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 - Google Patents

악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 Download PDF

Info

Publication number
KR20120036842A
KR20120036842A KR1020117029706A KR20117029706A KR20120036842A KR 20120036842 A KR20120036842 A KR 20120036842A KR 1020117029706 A KR1020117029706 A KR 1020117029706A KR 20117029706 A KR20117029706 A KR 20117029706A KR 20120036842 A KR20120036842 A KR 20120036842A
Authority
KR
South Korea
Prior art keywords
pde4d7
expression
prostate cancer
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117029706A
Other languages
English (en)
Korean (ko)
Inventor
랄프 호프만
마일즈 디. 하우스레이
데이비드 제이. 피. 헨더슨
Original Assignee
코닌클리케 필립스 일렉트로닉스 엔.브이.
더 유니버시티 코트 오브 더 유니버시티 오브 글래스고우
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코닌클리케 필립스 일렉트로닉스 엔.브이., 더 유니버시티 코트 오브 더 유니버시티 오브 글래스고우 filed Critical 코닌클리케 필립스 일렉트로닉스 엔.브이.
Publication of KR20120036842A publication Critical patent/KR20120036842A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04017—3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020117029706A 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 Ceased KR20120036842A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09159960 2009-05-12
EP09159960.5 2009-05-12
EP09169739 2009-09-08
EP09169739.1 2009-09-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177037100A Division KR102110469B1 (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7

Publications (1)

Publication Number Publication Date
KR20120036842A true KR20120036842A (ko) 2012-04-18

Family

ID=42352017

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117029706A Ceased KR20120036842A (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
KR1020177037100A Active KR102110469B1 (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177037100A Active KR102110469B1 (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7

Country Status (9)

Country Link
US (1) US8778621B2 (enExample)
EP (1) EP2430190B1 (enExample)
JP (4) JP2012526544A (enExample)
KR (2) KR20120036842A (enExample)
CN (1) CN102439176B (enExample)
BR (1) BRPI1007704A2 (enExample)
DK (1) DK2430190T3 (enExample)
ES (1) ES2707598T3 (enExample)
WO (1) WO2010131194A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101663675B1 (ko) 2016-07-27 2016-10-07 강성훈 유체 흐름 유도장치

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007093A2 (pt) * 2009-05-12 2017-06-06 Koninl Philips Electronics Nv fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer
JP2012526544A (ja) * 2009-05-12 2012-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
GB201504763D0 (en) 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses
BR112017025430B1 (pt) * 2015-05-29 2024-04-30 Koninklijke Philips N.V. Método, uso de um produto, produto de programa de computador e sistema
EP3303616B1 (en) 2015-05-29 2021-01-06 Koninklijke Philips N.V. Methods of prostate cancer prognosis
GB201616439D0 (en) 2016-09-28 2016-11-09 Mironid Limited Compounds and uses
BR112019011031A2 (pt) * 2016-12-01 2020-01-07 Koninklijke Philips N.V. Método para estratificação de risco, produto de programa de computador, kit de diagnóstico e uso de um perfil de expressão gênica para estratificação de risco
EP3502280A1 (en) * 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
EP3546598A1 (en) * 2018-03-29 2019-10-02 Koninklijke Philips N.V. Post-surgical risk stratification based on pde4d variant expression, selected according to tmprss2-erg fusion status, and post-surgical clinical variables
GB201805527D0 (en) 2018-04-04 2018-05-16 Mironid Ltd Compounds and their use as pde4 activators
EP3636779A1 (en) * 2018-10-11 2020-04-15 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 and dhx9 expression
CN111198270B (zh) * 2018-11-16 2023-04-07 山东泽济生物科技有限公司 一种用于甘油醛-3-磷酸脱氢酶磁微粒化学发光检测试剂盒及其制备方法
EP4360711A1 (en) * 2022-10-27 2024-05-01 Koninklijke Philips N.V. Treatment of prostate cancer by promoting pde4d7
WO2024088865A1 (en) 2022-10-27 2024-05-02 Koninklijke Philips N.V. Treatment of prostate cancer by promoting pde4d7
WO2025016918A1 (en) 2023-07-18 2025-01-23 Koninklijke Philips N.V. Prediction of an outcome of a subject suffering from a glioma
EP4600377A1 (en) 2024-02-12 2025-08-13 Koninklijke Philips N.V. Prediction of an outcome of a subject suffering from a glioma
EP4603836A1 (en) 2024-02-13 2025-08-20 Koninklijke Philips N.V. Prediction of an outcome of a prostate cancer subject
EP4620461A1 (en) 2024-03-22 2025-09-24 Koninklijke Philips N.V. Treatment of prostate cancer by inhibiting short pde4d isoforms
CN118726352B (zh) * 2024-06-28 2025-11-07 山东大学 启动子元件及其在3-羟基丙酸生物合成中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261562B1 (en) * 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
TR200100916T2 (enExample) * 1998-07-14 2002-06-21 Corixa@@Corporation
PL364135A1 (en) 2001-01-31 2004-12-13 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
IS7221A (is) * 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
US20030220273A1 (en) * 2002-05-15 2003-11-27 Isis Pharmaceuticals Inc. Antisense modulation of phosphodiesterase 4D expression
AU2003301894A1 (en) 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
AU2004284434A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR assay system for gene expression profiling
CN101018874A (zh) * 2004-08-13 2007-08-15 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
RS52274B2 (sr) * 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
BRPI0713111A2 (pt) * 2006-05-19 2012-04-17 Topigen Pharmaceuticals Inc oligonucleotìdeos que afetam a expressão das fosfodiesterases
JP2009540852A (ja) * 2006-07-03 2009-11-26 エグゾニ・テラピューティック・ソシエテ・アノニム 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用
WO2008009479A1 (en) * 2006-07-21 2008-01-24 Epigenomics Ag Methods and nucleic acids for analyses for cellular proliferative disorders
WO2009065511A2 (en) * 2007-11-23 2009-05-28 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
JP2012526544A (ja) * 2009-05-12 2012-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７
BRPI1007093A2 (pt) * 2009-05-12 2017-06-06 Koninl Philips Electronics Nv fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101663675B1 (ko) 2016-07-27 2016-10-07 강성훈 유체 흐름 유도장치

Also Published As

Publication number Publication date
ES2707598T3 (es) 2019-04-04
KR102110469B1 (ko) 2020-05-14
JP2017212973A (ja) 2017-12-07
JP2012526544A (ja) 2012-11-01
BRPI1007704A2 (pt) 2019-12-03
JP2016028245A (ja) 2016-02-25
JP6246167B2 (ja) 2017-12-13
KR20180002900A (ko) 2018-01-08
EP2430190A1 (en) 2012-03-21
WO2010131194A1 (en) 2010-11-18
CN102439176B (zh) 2018-11-23
US8778621B2 (en) 2014-07-15
DK2430190T3 (en) 2019-02-18
CN102439176A (zh) 2012-05-02
EP2430190B1 (en) 2018-11-21
US20120129788A1 (en) 2012-05-24
JP6588496B2 (ja) 2019-10-09
RU2011150264A (ru) 2013-06-20
JP2019205431A (ja) 2019-12-05

Similar Documents

Publication Publication Date Title
KR101778036B1 (ko) 전립선암 마커로서의 포스포디에스테라제 4ｄ7
KR102110469B1 (ko) 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
KR20210138587A (ko) 개선된 면역요법을 위한 조합 유전자 표적
CA2936612A1 (en) Atf6 polymorphisms associated with myocardial infarction, method of detection and uses thereof
CN113853437A (zh) 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
KR20230034198A (ko) 종양 침윤 림프구의 활성화 및 확장 방법
KR102236784B1 (ko) 성장 호르몬 수용체의 조절인자
KR20210027384A (ko) Scn9a 발현을 조절하기 위한 올리고뉴클레오티드
AU2016376191A1 (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
KR20180093902A (ko) 태아와 임신 여성간에 상이하게 메틸화된 디엔에이 영역을 이용한 태아 염색체 이수성의 검출
KR20220024184A (ko) 대장암의 검출
KR20220025749A (ko) 대장암의 검출
KR101621273B1 (ko) 카텝신 ｃ의 용도
KR20210144822A (ko) Ube3a-ats를 조절하기 위한 화합물 및 방법
CN1423696A (zh) 人类精神分裂症基因
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
KR20220025806A (ko) 핵산의 무작위 구성 표적화 통합
CN101151371B (zh) 治疗中的逆转录转座子抑制
KR20230074214A (ko) 지방간 질환의 치료 방법
KR20170116009A (ko) 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
CN111344408A (zh) 用于调控fndc3b表达的寡核苷酸
KR101474053B1 (ko) 골다공증 또는 골다공성 골절 발생 위험도 예측용 다형성 마커
KR102477906B1 (ko) 유도만능 줄기세포 분화 특이적 lncRNA, 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111212

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150511

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160323

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170123

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160323

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170123

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160922

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150511

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120103

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170306

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170925

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170804

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170306

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170223

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170123

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160922

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160323

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150511

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120103

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171222